GeniusAb™: A Fully Human Single-Domain Antibody Platform

Protheragen has launched GeniusAb™, a fully human single-domain antibody platform to produce high quality and customized antibodies for research, diagnostic and therapeutic use. This is a major breakthrough in the field of therapeutic antibodies as it is able to provide highly specific, robust, and versatile solutions to a variety of diseases.

Single-domain antibodies (sdAbs), also known as VHH antibodies or camelid antibodies, are derived from the immune systems of camels and llamas. Unlike conventional antibodies, the unique structure of sdAbs allows them to bind to targets with high affinity and selectivity while maintaining stability and ease of production. These advantages make sdAbs a promising tool in biotechnology and therapeutics.

To reduce the costs and time involved in identifying new therapeutic single-domain antibodies from species such as camels and sharks, Protheragen has found a way to do so: the GeniusAb™ mice. These genetically engineered mice are designed to produce fully human single-domain antibodies. By leveraging these mice, researchers can avoid the need for in vitro humanization, leading to a more streamlined and economical process.

Protheragen’s GeniusAb™ mouse model boasts several advantages, including:

• Robust immune responses to diverse antigens: The GeniusAb™ mouse models have a rich repertoire of B cells capable of recognizing and responding to different antigens, including proteins, peptides, and pathogens.

• Sequence diversity and optimal affinity: By incorporating human antibody gene segments and implementing genetic modifications, GeniusAb™ mice exhibit a variety of antibody sequences that closely mimic those present in humans, which can enable the examination of a wide array of antibody variants and enhance the likelihood of discovering antibodies with ideal affinity and specificity for the desired target.

• Excellent developability: Antibodies produced from GeniusAb™ mice possess advantageous traits, including stability, solubility, low immunogenicity, and compatibility with subsequent manufacturing processes, paving the way for the development and commercialization of antibody-based therapeutics and diagnostics.

The GeniusAb™ platform harnesses the unique properties of single-domain antibodies while ensuring that they are entirely compatible with the human immune system. This innovation opens new avenues for drug discovery and development, allowing researchers to tackle previously challenging targets with unmatched precision and efficacy.